NCM·Healthcare·$54M·#496 / 520 in Healthcare
TIL Instil Bio, Inc.
18CRITICAL
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY13
VALUATION50
GOVERNANCE58
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
2 months
4
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
74.8%
33
< 25% strong
Price / Sales
Market cap relative to trailing revenue
N/A
50
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
6.3%
46
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+3.4%
80
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE TIL WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
7 Best Small-Cap Biotech Stocks for 2026 (Cash + Pipeline)Apr 3, 202610 Best Small-Cap Stocks to Buy for Q2 2026 (Ranked)Apr 3, 2026SCORE ALERT
Get notified when TIL's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.